TB-500 Research Grade Quality: COA Analysis, HPLC Purity, and Mass Spectrometry

Why Research Grade Matters for TB-500

TB-500 is synthesized via solid-phase peptide synthesis (SPPS), a process that produces not just the target heptapeptide (Ac-LKKTETQ) but also truncated sequences, deletion analogs, oxidation products, and aggregates as synthesis by-products. These impurities can compete with TB-500 for actin binding, generate artifacts in cell-based assays, and compromise the interpretability of preclinical data.

The purity and identity of the final product directly determine whether research results reflect TB-500's true biology. A Certificate of Analysis (COA) provides documented analytical evidence of peptide identity and purity from the manufacturing batch. Understanding how to interpret a COA is a fundamental competency for researchers selecting TB-500 for preclinical work.

Solid-Phase Peptide Synthesis and Common Impurities

TB-500 (Ac-LKKTETQ) is synthesized by Fmoc-based solid-phase peptide synthesis:

• C-terminal residue (Gln) is anchored to resin via acid-labile linker
• Fmoc deprotection and sequential coupling of each amino acid
• N-terminal acetylation (Ac- cap) as final modification step
• Acid cleavage from resin with simultaneous side-chain deprotection (TFA cocktail)
• Preparative HPLC purification
• Lyophilization of purified fractions to dry powder

Common SPPS Impurities in TB-500

Impurity Type

Origin

Detection Method

Truncated sequences	Incomplete coupling at any residue	RP-HPLC (earlier elution), MS
Deletion peptides	Skipped residue during synthesis	MS (mass shift equal to deleted AA MW)
N-terminal failure sequences	Incomplete acetylation	MS (delta -42 Da vs. correct product)
Asp-Glu rearrangement	Aspartimide formation at Asp	MS (+18 Da shift, acidic pH favored)
Aggregates/dimers	Concentration and storage effects	SEC-HPLC, dynamic light scattering
TFA counter-ion residue	Cleavage/purification chemistry	Ion chromatography, titration
Residual acetic acid	Lyophilization solvent carryover	pH measurement, ion chromatography

HPLC Purity Analysis

Reversed-Phase HPLC (RP-HPLC)

RP-HPLC on C18 or C8 stationary phases is the standard purity assessment technique for peptides. The method separates compounds by hydrophobicity using an acetonitrile/water gradient with 0.1% TFA. UV detection at 214 nm measures peptide bond absorbance for all-peptide quantification:

• Each peak in the chromatogram represents a distinct molecular species
• Purity (%) = [Target peak area divided by total peak area] x 100
• Peak identity confirmed by fraction collection and mass spectrometry
• System suitability requires baseline resolution (Rs > 1.5) between adjacent peaks

TB-500 Purity Standards by Research Application

Purity Grade

HPLC Purity

Application Suitability

Research grade	95% or higher	Standard preclinical research, in vivo studies
High purity	98% or higher	Mechanistic, signaling, and receptor studies
Pharmaceutical grade	99% or higher (GMP)	Clinical trial materials only
Crude or technical	70-85%	Unsuitable for biological research

For TB-500 preclinical research, 95% or higher purity by RP-HPLC is the minimum acceptable standard. Studies reporting biological effects with less than 95% material risk attributing peptide-driven effects to uncharacterized impurities.

Reading a TB-500 HPLC Chromatogram

Key features to verify on a COA-provided chromatogram:

• Single dominant main peak with clean baseline return on both sides
• No large unresolved shoulders (which would inflate apparent purity)
• Total impurity area less than 5% for a 95% purity specification
• Baseline noise level appropriate for the detector sensitivity claimed
• Retention time consistent with the expected hydrophobicity of Ac-LKKTETQ (relatively early-eluting due to hydrophilic sequence)

Mass Spectrometry Identity Confirmation

HPLC purity tells you a compound is present at high abundance - mass spectrometry confirms which compound it is. Both analyses are required for full quality assessment.

Expected MS Parameters for TB-500

• Peptide sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln
• Molecular formula: C33H61N9O14 (for the acetylated neutral form)
• Average molecular weight: ~808 Da (for the LKKTETQ fragment; note that the commonly cited ~2,100 Da refers to older characterizations of a longer fragment)
• ESI-MS expected ions: [M+H]+ (singly charged), [M+2H]2+ (doubly charged)
• MALDI-TOF: [M+H]+ ion at calculated monoisotopic mass within 0.1 Da
• Salt form: Often supplied as TFA salt (adds ~113 Da per TFA molecule; noted in COA)

MS Red Flags

Finding

Interpretation

Action

Mass shift of +16 Da	Methionine oxidation (no Met in TB-500: suggests wrong peptide)	Reject batch
Mass shift of -1 Da on Gln	Deamidation (Gln to Glu), common degradation	Assess severity; check storage
Multiple major MS peaks	Impurity mixture, failed synthesis	Reject batch
No ion at expected mass	Wrong peptide entirely	Reject batch; contact supplier
Mass consistent but HPLC low	Coeluting impurities at same mass	Request extended HPLC method	What a Complete TB-500 COA Should Include	Analysis	Method	Acceptance Criterion

Purity	RP-HPLC at 214 nm	95% or higher
Identity	ESI-MS or MALDI-TOF	Observed MW within 0.1 Da of theoretical
Appearance	Visual inspection	White to off-white lyophilized powder
Solubility	Water or BAC water test	Clear solution at 1 mg/mL or higher
Water content	Karl Fischer titration	8% or lower (lyophilized)
Amino acid analysis (optional)	Acid hydrolysis followed by HPLC	Correct residue molar ratios
Endotoxin (optional for cell studies)	LAL (limulus amebocyte lysate) assay	Less than 1 EU/mg

Why Actin-Binding Bioactivity Requires High Purity

TB-500's mechanism depends on precise molecular recognition: the LKKTETQ sequence binds G-actin at the WH2 (Wasp homology 2) domain-binding interface with defined stereochemical requirements. Truncated analogs missing one or more residues may:

• Bind actin with reduced affinity, competing with TB-500 without activating migration
• Alter the dose-response curve in scratch assay experiments
• Activate partial agonist responses in some signaling pathways
• Generate artifactual results in actin co-sedimentation assays

This mechanistic precision makes purity verification non-optional for any mechanistic TB-500 research where actin interaction is being studied.

Evaluating Supplier COA Quality

When assessing a TB-500 COA from any research peptide supplier:

• Confirm the COA shows the actual HPLC chromatogram image, not just a stated percentage
• Verify MS data shows the expected mass spectrum with correct ion assignments
• Ensure the batch number printed on the COA matches the vial label exactly
• Check COA date: request updated testing if the document is more than 18 months old for refrigerated lyophilized stock
• Confirm testing was performed by the supplier's own analytical laboratory or a named third-party analytical service

For laboratory research only. Not for human administration.